[Female reproductive function after radioiodine therapy for differentiated thyroid carcinoma]

Differentiated thyroid carcinoma (DTC) is the most common endocrine cancer, accounting for 90-95% of thyroid malignancy and predominant in the female population of all age groups. Surgery is the standard primary treatment for patients with DTC, followed by radioactive iodine therapy (RAIT) when indicated. After the main treatment, patients receive thyroid hormone therapy in a variety of regimens, either as a replacement therapy or as a therapy intended to suppress secretion of thyroid-stimulating hormone (TSH).The impact of RAIT on the health of individuals with DTC has been studied for years. The accumulation of 131I in organs and tissues, as well as some organs' direct involvement in the metabolism of 131I-containing substances and its excretion, can lead to secondary complications. Reproductive health in the context of RAIT has also been a popular research topic because DTC is frequently found in young individuals.We may identify a direction for future study in this field and the requirement for adjustments in patient management thanks to the data summarized in this review on the effect of RAIT for DTC on female reproductive health.